BMED, established in 2017, has taken its place in the Turkish pharmaceutical industry with its products used in the treatment of rare diseases.
BMED, established in 2017, has taken its place in the Turkish pharmaceutical industry with rare disease treatments.
The target of BMED, which has partnerships with the world's leading pharmaceutical companies, is to ensure that rare treatments are delivered to patients easily, safely and quickly, within the framework of ethical and scientific values and with an understanding of quality products.
It brings together the products used in the treatment of rare diseases in many branches, especially in Endocrinology, Organ Transplantation, Oncology, Hematology, Cardiology, and Rheumatology, and works devotedly in the treatment of rare diseases.
Headquartered in Ankara, BMED also has offices in Istanbul. BMED carries out the sales and marketing of the products in its portfolio to a wide geography in Turkey with its field staff.
In this direction, BMED, with 26 different partners from 15 different countries, enables patients to reach the treatments needed in Turkey. BMED constantly enriches its portfolio and continues on its way in line with its target of becoming the largest pharmaceutical company in the treatment of rare diseases in Turkey.",
